SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-19-009295
Filing Date
2019-05-09
Accepted
2019-05-09 16:06:53
Documents
70
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20190331_10q.htm 10-Q 790834
2 EXHIBIT 10.1 ex_142976.htm EX-10.1 127142
3 EXHIBIT 31.1 ex_142977.htm EX-31.1 9361
4 EXHIBIT 32.1 ex_142978.htm EX-32.1 4875
  Complete submission text file 0001437749-19-009295.txt   5417440

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT navb-20190331.xml EX-101.INS 1035940
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20190331.xsd EX-101.SCH 52416
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20190331_cal.xml EX-101.CAL 38566
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20190331_def.xml EX-101.DEF 484671
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20190331_lab.xml EX-101.LAB 342370
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20190331_pre.xml EX-101.PRE 498494
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 19810529
SIC: 2835 In Vitro & In Vivo Diagnostic Substances